

Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)

Technology appraisal guidance
Published: 13 June 2024

www.nice.org.uk/guidance/ta982

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of baricitinib for treating juvenile idiopathic arthritis in people 2 years and over. This is because Eli Lilly has confirmed that it does not intend to make an evidence submission for the appraisal. Eli Lilly considers that the technology will not be launched in England and Wales for treating this indication.

Information

If NHS organisations wish to consider baricitinib for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6159-7